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ABSTRACT Bacterial and mammalian mismatch repair
systems have been implicated in the cellular response to
certain types of DNA damage, and genetic defects in this
pathway are known to confer resistance to the cytotoxic effects
of DNA-methylating agents. Such observations suggest that in
addition to their ability to recognize DNA base-pairing errors,
members of the MutS family may also respond to genetic
lesions produced by DNA damage. We show that the human
mismatch recognition activity MutSa recognizes several types
ofDNA lesion including the 1,2-intrastrand d(GpG) crosslink
produced by cis-diamminedichloroplatinum(II), as well as
base pairs between O6-methylguanine and thymine or cytosine,
or between 04-methylthymine and adenine. However, the protein
fails to recognize 1,3-intrastrand adduct produced by trans-
diamminedichloroplatinum(H) at a d(GpTpG) sequence. These
observations imply direct involvement of the mismatch repair
system in the cytotoxic effects of DNA-methylating agents and
suggest that recognition of 1,2-intrastrand cis-diamminedichlo-
roplatinum(ll) adducts by MutSa may be involved in the cyto-
toxic action of this chemotherapeutic agent.
Strand-specific mismatch repair systems have been described
in both bacteria and eukaryotic cells. The Escherichia coli
methyl-directed repair system acts on newly replicated DNA to
correct biosynthetic errors that have escaped the proofreading
function of the replicative DNA polymerase (1, 2). Biochem-
ical analysis of the methyl-directed reaction has demonstrated
that products of the mutS and mutL genes play key roles in
initiation of the excision reaction, which removes an incor-
rectly inserted nucleotide from the new DNA strand. The
MutS protein is responsible for mismatch recognition (3, 4),
with subsequent binding of MutL to the MutS-mismatch
complex (5), probably serving to interface mismatch recogni-
tion by MutS to activities required for subsequent steps of
repair (6, 7).
In addition to their roles in the processing of mismatched
Watson-Crick bases, bacterial MutS and MutL have been
implicated in cellular responses to certain types of DNA
damage. E. coli mutS and mutL mutants are resistant to the
cytotoxic effects of DNA damage produced by N-methyl-N'-
nitro-N-nitrosoguanidine (MNNG; refs. 8 and 9) and cis-
diamminedichloroplatinum(II) (cisplatin or cis-DDP) (10).
Products of the bacterial mut genes have also been implicated
in UV-induced recombination (11, 12) and transcription-
coupled repair of pyrimidine dimers (13). Although the sim-
plest interpretation of these observations is that interaction of
MutS and MutLwith MNNG-, cisplatin-, or UV-induced DNA
damage plays a role in cellular responses to such lesions, the
ability of bacterial MutS to recognize damage produced by
these agents has not been reported. Consequently the distinc-
tion between direct versus indirect participation of MutS and
MutL in these effects has been uncertain.
Mammalian cells have a mismatch repair system that is
similar to the bacterial pathway with respect to specificity,
mechanism, and dependence on proteins homologous to MutS
and MutL (2, 14). In human cells the MutSa heterodimer
(hMutSa), comprised of the MutS homologs MSH2 and
GTBP/p160, is apparently sufficient to provide the mismatch
recognition function (15, 16), while MutL function is provided
by the MutLa heterodimer of MLH1 and PMS2 (17). Defects
in any of the four genes encoding these polypeptides results in
a mutator phenotype (18-20) and mismatch repair deficiency
(15, 20-25).
Selection of mammalian cell lines resistant to the cytotoxic
effects of MNNG or N-methyl-N-nitrosourea (MNU) fre-
quently yields mutants deficient in mismatch repair (21, 26,
27). Conversely, at least some mismatch repair-deficient cell
lines are resistant to killing by these agents (28). Genetic
analysis of several MNU- and MNNG-resistant cell lines has
demonstrated that resistance is associated with deficiency of
MLH1 or GTBP/p160 (20, 28), but cell lines deficient in the
other subunits of MutLa or MutSa have not been tested for
this phenotype. The alkylation-tolerant phenotype associated
with mismatch repair deficiency has been interpreted in terms
of direct participation of the repair system in the sequence of
events that results in cell death upon exposure to MNNG or
MNU (21, 29). However, because recognition of MNNG or
MNU damage by mammalian MutSa has not been demon-
strated, an indirect role of the repair system in the cytotoxic
response to these agents has not been excluded.
The involvement of MutS and MutL activities in cellular
responses to DNA damage coupled with their established role
in rectification of DNA metabolic errors has led to the
suggestion that these proteins may serve as general sensors of
genetic damage (21, 28). Indeed, repair-deficient, alkylation-
tolerant cell lines display a G2 checkpoint defect upon chal-
lenge with MNNG (18) or exposure to the base analog
6-thioguanine (30). We report here that human MutSa effi-
ciently recognizes several forms of DNA damage, including
base pairs involving 06-methylguanine (O6meG), O4-
methylthymine (04meT), and the cisplatin-(GpG) adduct. Our
findings are consistent with a direct role of the human mis-
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Nucleotides shown in boldface type indicate the location of a G-T mispair or DNA
lesion after hybridization with the appropriate complementary strand.
match recognition activity in the cytotoxic response provoked
by certain types of DNA damage.
MATERIALS AND METHODS
Proteins and Oligonucleotides. Human MutSa was purified
as described (15). Oligonucleotides used in this study (Table 1;
purchased from Oligos Etc., Wilsonville, OR) were purified by
gel electrophoresis through 20% polyacrylamide (wt/vol) in
the presence of 7 M urea. Oligonucleotides were recovered by
excision of bands, electroelution, and ethanol precipitation.
Platinated derivatives of oligonucleotides 9, 10, and 11 (Table
1) were prepared by reaction with 0.1 mM cis-DDP (cisplatin;
Aldrich) or trans-DDP (transplatin; Aldrich) in 100 ,ul of 10
mM Tris HCl (pH 7.5) for 24 h at 37°C (31, 32). Unreacted
cisplatin or transplatin was removed by chromatography on
Sephadex G25 (Pharmacia), platinated DNA precipitated with
three volumes of ethanol, and purified by denaturing gel
electrophoresis (32). The cis- and transplatinated oligonucle-
otides were significantly retarded relative to unreacted oligo-
nucleotide. Oligonucleotides were labeled using [y-32P]ATP
(3000 Ci/mmol; DuPont/NEN) and T4 polynucleotide kinase
(Amersham), and unincorporated label was removed by chro-
matography on Sephadex G25.
Duplex molecules were constructed by mixing approximate
molar equivalents of a [5'-32P]-oligonucleotide with an unla-
beled complementary sequence. The solution was heated to
90°C in 10 mM Tris HCl (pH 7.5) and 100 mM KCI and slow
cooled to 15°C over 90-min period using a Perkin-Elmer Gene
Amp 9600 thermocycler.
Gel Electrophoretic Retardation Assay. Reactions (15 ,A)
contained 10 mM Hepes-KOH (pH 7.6), 100 mM KCl, 5 mM
MgCl2, 1 mM dithiothreitol, 50 mg of bovine serum albumin
per ml, [5'-32P]oligonucleotide duplex (10 fmol), unlabeled
31-bp duplex competitor (200 fmol, oligonucleotides 4 and 7 in
Table 1), and hMutSa heterodimer as indicated. After 10-min
incubation on ice, reactions were supplemented with 1.5 ,ul of
10 mM Hepes, pH 7.6/50% sucrose. Samples were immedi-
ately loaded onto a 6% polyacrylamide gel [36:1 acrylamide/
bisacrylamide (wt/wt)] and subjected to electrophoresis at 4°C
in 20 mM Tris-acetate (pH 7.6), 1 mM MgCl2 at 8 V/cm with
buffer recirculation (1 liter/h). Gels were dried onto Whatman
3-MM paper and autoradiographed at -70°C using Kodak
Biomax x-ray film with Ilford fast tungstate intensifier screens.
In some cases the relative amounts of DNA species were
quantitated using a Molecular Dynamics Phosphorlmager.
RESULTS
hMutSa Binds to Base Pairs Containing 06-Methylguanine
or 04-Methylthymine. The DNA-methylating agents MNNG
and MNU are both mutagenic and cytotoxic. Because inacti-
vation of the 06-methylguanine-DNA methyltransferase ren-
ders cells hypersensitive to mutagenesis and killing by these
agents (33), both effects have been attributed to DNA lesions
processed by this activity, namely O6meG and, to a lesser
degree, 04meT in the case of the human protein (21, 29, 34).
Because a functional mismatch repair system has been impli-
cated in the cytotoxic effect of MNNG and MNU on mam-
malian cells (21, 26-28), we have used gel retardation assay to
test human MutSa for its ability to recognize base pairs
containing O6meG and 04meT. In the presence of excess
homoduplex competitor DNA, hMutSa binds specifically and
with similar affinities to 31-bp oligonucleotide duplexes con-
taining either an O6meG-C or an O6meG-T base pair (Fig. 1).
The latter nucleotide pair expected to occur at significant
frequency upon replication of a DNA template containing
O6meG (35). We estimate the binding constants that govern
interaction of protein with these O6meG-containing base pairs
to be about an order of magnitude less than that for a G-T
mismatch (compare Fig. 1 with lane 2 of Fig. 2). Human MutSa
binds with similar affinity to an oligonucleotide duplex con-
taining an 04meT-A base pair, but binds only weakly to an





FIG. 1. MutSa binds to 06meG-C and 06meG-T base pairs. Gel
shift binding assays were performed in reactions containing 12 nM
G-C homoduplex competitor (oligonucleotides 4 and 7) and 0.6 nM
5'-32P-labeled 06meG-C heteroduplex (oligonucleotides 1 and 7) or
06meG-T heteroduplex (oligonucleotides 1 and 8). The concentration
of hMutSa heterodimer was varied in each series (0 nM, 0.8 nM, 1.6
nM, 3.3 nM, 6.6 nM, 13 nM, or 26 nM) as indicated.
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FIG. 2. hMutSa binds to the 04meT-A base pair. Binding reactions
contained 12 nM G-C homoduplex competitor (oligonucleotides 4 and
7) and 0.6 nM 5'-32P-labeled G-T (oligonucleotides 4 and 8), 04meT-A
(oligonucleotides 2 and 5), or 04meT-G (oligonucleoties 2 and 6)
heteroduplexes as indicated. In the G-T reactions shown in the left two
lanes, hMutSa was either absent or present at 2.6 nM. In the 04meT-A
and 04meT-G reaction series, hMutSa concentration was varied (0
nM, 3.3 nM, 6.6 nM, 13 nM, or 26 nM) as indicated.
eight possible base mispairs, hMutSa binds with highest af-
finity to the G-T mismatch, which we have used here as the
basis for comparison, but exhibits reduced affinity for other
mispairs that are nevertheless corrected by the human repair
system (D.R.D., J.T.D., and P.M., unpublished data). Conse-
quently, binding affinities for O6meG-C, O6meG-T, and
04meT-A pairs described here would be consistent with
elicitation of a biological response.
In addition to their resistance to MNNG and MNU, mis-
match repair-deficient mammalian cells are also resistant to
the cytotoxic effects of the base analog 6-thioguanine (S6G;
refs. 30 and 36), an effect that may be due to structural
similarities between S6G and O6meG (30, 37). Experiments
similar to those shown in Figs. 1 and 2 have demonstrated that
hMutSa binds to a 31-bp duplex that contains one S6G-T base
pair (oligonucleotides 3 and 8 in Table 1) with an affinity
similar to that for DNAs containing O6meG (data not shown).
However, the protein binds only weakly to an otherwise
identical 31-bp duplex containing a S6G-C base pair.
hMutSa Binds to Cisplatinated GpG. The cis isomer of
DDP (cisplatin or cis-DDP) displays antibacterial and anti-
cancer activity, but the trans isomer (transplatin or trans-DDP)
does not (reviewed in refs. 38 and 39). The major products of
cisplatination of DNA are 1,2-intrastrand crosslinks between
purine N7 atoms in the dinucleotide sequences d(GpG) (65%)
and d(ApG) (25%), with minor products including the
1,3-crosslink between guanines in trinucleotide sequence
d(GpNpG) (6%) and monoadducts (40). Steric constraints
preclude formation of 1,2-intrastrand crosslinks by transpla-
tin, although this isomer can form 1,3-crosslinks (41).
E. coli mutL mutations confer resistance to the cytotoxic
effects of cisplatin (10), and human cell lines resistant to
cisplatin have been found to display frequent mutations in
microsatellite sequences and attenuation of p53 function (42).
Because the former phenotype is often associated with mis-
match repair deficiency (43), we have tested the affinity of
hMutSa for several cisplatin adducts as well as the transplatin
1,3-intrastrand-d(GpTpG) crosslink. As shown in Fig. 3,
hMutSa binds tightly to the cisplatin 1,2-d(GpG) crosslink, but





FIG. 3. hMutSa binds to cisplatin 1,2-d(GpG) but not transplatin
1,3-d(GpTpG) adducts. Binding reactions contained 12 nM G-C
homoduplex competitor (oligonucleotides 4 and 7), 0.6 nM 5'-32P-
labeled duplexDNA containing a single cisplatin 1,2-d(GpG) crosslink
(cisplatinated oligonucleotide 9 hybridized to oligonucleotide 12) or a
single transplatin 1,3-d(GpTpG) adduct (transplatinated oligonucle-
otide 11 hybridized to oligonucleotide 14). Concentration of hMutSa
was varied (0 nM, 0.8 nM, 1.6 nM, 3.3 nM, 6.6 nM, 13 nM, or 26 nM)
as indicated.
The specificity of hMutSa for the cisplatin 1,2-d(GpG)
adduct was further assessed by competition methods. Com-
plexes of the human protein with a 31-bp G-T heteroduplex or
a 32-bp duplex containing a cisplatin 1,2-d(GpG) crosslink
were similarly resistant to competition by a 31-bp homoduplex
competitor, with binding reduced only 20-40% by a 160-fold
molar excess of the competing DNA (Fig. 4, Upper). Further-
more, the oligonucleotide duplex containing a cisplatin 1,2-
d(GpG) crosslink effectively competed with the G-T hetero-
duplex for hMutSa binding, whereas a similar duplex contain-
ing a transplatin 1,3-d(GpTpG) adduct did not (Fig. 4, Lower).
Fifty percent inhibition of G-T heteroduplex binding occurred
at a -20:1 molar ratio of the cisplatin 1,2-d(GpG) duplex to the
G-T substrate, indicating a binding constant for the cisplatin
1,2-d(GpG) crosslink about an order of magnitude less than
that for a G-T mispair. As mentioned above, binding constants
of this magnitude are consistent with production of a biological
response.
As observed with the transplatin 1,3-crosslink, we have
found that hMutSa binds poorly to the cisplatin 1,2-d(ApG) or
1,3-d(GpTpG) adducts. In the sequence contexts employed
here, the human protein thus displays high specificity for the
1,2-intrastrand crosslink produced by cisplatination of the
d(GpG) dinucleotide.
DISCUSSION
Observations implicating mismatch repair in the cellular re-
sponse to certain types of DNA damage have been attributed
to recognition of DNA lesions by components of this repair
system (8-10, 21, 29), but direct evidence on this point has
been lacking. Our results show that human MutSa efficiently
recognizes O6meG-C, O6meG-T, and 04meT-A base pairs.
Because the cytotoxicity of MNNG and MNU are largely
attributable to the production of O6meG (18, 33), this binding
specificity is consistent with direct participation of the human
mismatch repair system in the cytotoxic response that occurs
upon cellular exposure to these DNA-alkylating agents.
We have also shown that hMutSa binds with high specificity
to the cisplatin 1,2-d(GpG) crosslink, the major product
produced upon cisplatination of duplex DNA (42). Neverthe-
less, the protein fails to bind with detectable affinity to the
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FIG. 4. Specificity of hMutSa for a cisplatin 1,2-d(GpG) adduct by
competition assay. (Upper) Binding of hMutSa to a G-T heteroduplex
(oligonucleotides 4 and 8) or to a duplex containing a single cisplatin
1,2-d(GpG) crosslink (cisplatinated oligonucleotide 9 and oligonucle-
otide 12) in the presence of competitor G-C homoduplex DNA
(oligonucleotides 4 and 7). Binding reactions contained 0.6 nM
5'-32P-labeled G-T heteroduplex or cisplatinated duplex, and 4 nM
(G-T reactions) or 10 nM [cisplatin 1, 2-d(GpG) reactions] hMutSa.
Unlabeled homoduplex competitor was present as indicated on the
abscissa [-o-, hMutSa-G-T complexes; and ---, hMutSa-cisplatin
1,2-d(GpG) complexes]. (Lower) Binding of hMutSa to G-T hetero-
duplex in the presence of unlabeled competitor DNA containing a
single cisplatin 1,2-d(GpG) or a single transplatin 1,3-d(GpTpG)
adduct (transplatinated oligonucleotide 11 hybridized to oligonucle-
otide 14). Binding reactions contained 0.6 nM 5'-32P-labeled G-T
heteroduplex, 2 nM hMutSa, and unlabeled cisplatinated or transpla-
tinated competitor as indicated [-o-, cisplatin 1, 2-d(GpG) competitor;
and ---, transplatin 1,3-d(GpTpG) competitor].
1,3-intrastrand adduct produced by transplatin, a compound
that cannot produce 1,2-crosslinks and displays little cytotox-
icity and no anticancer activity (10, 38, 41). As noted above, E.
coli mutants deficient in mismatch repair are resistant to the
cytotoxic effects of cisplatin, and human cell lines resistant to
cisplatin exhibit frequent mutations in microsatellite se-
quences and apparent attenuation of p53 function (42), with
the former phenotype characteristic of mismatch repair defi-
ciency (43). In fact, we have recently found several cisplatin-
resistant human cell lines to be deficient in mismatch repair
(J.T.D., R. Brown, and P.M., unpublished data). Recognition
of the cisplatin 1,2-d(GpG) adduct by hMutSa may therefore
play a role in the cytotoxic action of this anticancer compound.
It is important to note that proteins of the high mobility group
(HMG) family also bind to cisplatin 1,2-crosslinks (44, 45).
Binding ofHMG domain proteins has been found to inhibit in
vitro repair of 1,2-d(GpG) adducts by the human excision
repair system (46), and deficiency of the Saccharomyces cer-
evisiae IXRI product, which contains an HMG box, is associ-
ated with increased resistance to cisplatin (47). To our knowl-
edge, however, genetic alteration of the intracellular levels of
HMG proteins has not been described in cisplatin-resistant
mammalian cells.
Although mismatch repair defects have been implicated in
the cytotoxicity of MNNG, MNU, and cisplatin, the mecha-
nism by which lesion recognition by this system leads to cell
death is still uncertain. The favored model suggests that cell
killing results from translesion synthesis when the replication
fork encounters a miscoding adduct in the template strand (18,
33), with the presence of the ensuing base pair anomaly in the
newly replicated region provoking mismatch repair. Because
action of this system is restricted to the new DNA strand, the
offending lesion remains in the parental template leading to
turnover of newly synthesized DNA by a reiterative process of
excision and resynthesis, an effect postulated to result in cell
death. It is important to note, however, that alternate mech-
anisms have not been excluded. For example, it is possible that
recognition of damaged base pairs by hMutSa may lead to cell
death by interface with systems other than the excision path-
way involved in processing of replication errors. It is interesting
to note that precedent for differential fates of a mismatch-
MutS complex is available in the E. coli system. For example,
the MutS- and MutL-dependent fate of G-T mismatch depends
on its origin as a replication error or as the product of
deamination of 5-methylcytosine in 5-methylcytosine-guanine
base pair in resting DNA (reviewed in refs. 6 and 48). A similar
phenomenon has been described with respect to function of
MutS and MutL in recombination fidelity where the two
proteins act in concert to block recombinational exchanges
between DNA sequences that have diverged at the nucleotide
level (49, 50). This effect, which has been attributed to
recognition of mismatched base pairs within the recombina-
tion heteroduplex (51, 52), is apparently independent of the
excision system that removes replication errors (49, 50). The
fate of DNA lesion recognized by bacterial MutS family can
therefore depend on the context in which it was produced.
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